Biomotion Sciences Ordinary Shares Net Assets
Biomotion Sciences Ordinary Shares net assets. Based on the latest financial reports, Biomotion Sciences Ordinary Shares (SLXN) has net assets worth $44.00K USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.25 Million) and total liabilities ($4.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Biomotion Sciences Ordinary Shares annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $44.00K |
| % of Total Assets | 1.04% |
| Annual Growth Rate | N/A |
| 5-Year Change | -97.73% |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of Biomotion Sciences Ordinary Shares (2020–2025)
Net assets of Biomotion Sciences Ordinary Shares from 2020 to 2025. This chart illustrates how Biomotion Sciences Ordinary Shares's net assets have evolved over time, based on quarterly financial data. See net asset quality index of Biomotion Sciences Ordinary Shares to measure how much of total assets are equity-financed.
Annual Net Assets for Biomotion Sciences Ordinary Shares (2020–2025)
The table below shows the annual net assets of Biomotion Sciences Ordinary Shares from 2020 to 2025. For live market cap and overall valuation, see Biomotion Sciences Ordinary Shares market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.60 Million | +165.25% |
| 2024-12-31 | $-3.99 Million | +66.91% |
| 2023-12-31 | $-12.06 Million | -70.31% |
| 2022-12-31 | $-7.08 Million | -106.16% |
| 2021-12-31 | $114.91 Million | +67694.90% |
| 2020-12-31 | $-169.99K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biomotion Sciences Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5497014000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Biomotion Sciences Ordinary Shares Net Assets Breakdown (December 2025)
Biomotion Sciences Ordinary Shares net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $42.00K | 1.61% |
| Other Components | $57.73 Million | 2217.71% |
| Total Equity | $2.60 Million | 100.00% |
Biomotion Sciences Ordinary Shares Competitors by Market Cap
The table below lists competitors of Biomotion Sciences Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ovoca Gold PLC
IR:OVXA
|
$856.42K |
|
East Star Resources PLC
LSE:EST
|
$856.58K |
|
Accelerate Diagnostics Inc
NASDAQ:AXDX
|
$859.92K |
|
GACM Technologies Limited
NSE:GATECHDVR
|
$861.49K |
|
Superior Mining International Corp
V:SUI
|
$850.41K |
|
Hotel Fast SSE AB (publ)
ST:MAXENT-B
|
$848.25K |
|
Magnum Goldcorp Inc
V:MGI
|
$847.35K |
|
Blockchaink2 Corp
V:BITK
|
$846.53K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biomotion Sciences Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -3,989,000 to 2,603,000, a change of 6,592,000.
- Net loss of 11,912,000 reduced equity.
- New share issuances of 18,680,000 increased equity.
- Other factors decreased equity by 176,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.91 Million | -457.63% |
| Share Issuances | $18.68 Million | +717.63% |
| Other Changes | $-176.00K | -6.76% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Biomotion Sciences Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-0.10 | $0.15 | x |
| 2021-12-31 | $69.62 | $0.15 | x |
| 2022-12-31 | $-956.42 | $0.15 | x |
| 2023-12-31 | $-20777.62 | $0.15 | x |
| 2024-12-31 | $-959.36 | $0.15 | x |
| 2025-12-31 | $19.58 | $0.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biomotion Sciences Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -457.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.77x
- Recent ROE (-457.63%) is below the historical average (-76.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-178.86K |
| 2021 | -0.66% | 0.00% | 0.00x | 1.00x | $-12.25 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.15 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.39 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.04 Million |
| 2025 | -457.63% | 0.00% | 0.00x | 2.77x | $-12.17 Million |
Industry Comparison
This section compares Biomotion Sciences Ordinary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biomotion Sciences Ordinary Shares (SLXN) | $44.00K | 0.00% | 95.50x | $852.39K |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Biomotion Sciences Ordinary Shares
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for … Read more